14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
AVDL vs FOLD
Tradestie Institutional Equity Comparison Engine · Market Close Apr 24, 2026
AVDL vs FOLD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AVDL Captures Overall Composite Edge (62.9 BUY vs 59.4 HOLD), While FOLD Leads 4–2 on Growth & Valuation Pillars
AVDL Overall Winner
6-Pillar Tally: AVDL 2 – 4 FOLD
Matrix Metrics: AVDL 5 – 5 FOLD
As of Apr 24, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Amicus Therapeutics, Inc (FOLD) on higher Unified Composite conviction (62.9/100 BUY vs. 59.4/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Profitability & Quality), while FOLD wins 4–2 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus FOLD at $14.49 (17.7x Forward P/E, 8.6% operating margin).
Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. FOLD 59.4/100 HOLD) and 0.14β · 2% Vol risk profile, whereas FOLD leads top-line expansion (+23.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
AVDL
NASDAQ
Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
Market Cap
$2.1B
TTM Revenue
$249M
Forward P/E
28.8x
Beta / 30D Vol
0.14β · 2% Vol
Unified Composite Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
FOLD
NASDAQ
Amicus Therapeutics, Inc
Pharmaceutical Preparations
Market Cap
$4.5B
TTM Revenue
$634M
Forward P/E
17.7x
Beta / 30D Vol
0.27β · 2% Vol
Unified Composite Score
59.4 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 71.0
Mom 46.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 70
RSI-14: 70.4 · SMA20: $14.46 · SMA50: $14.40
6-Pillar Scorecard Institutional Category Breakdown (AVDL 2 – 4 FOLD)
Columns: Metric · AVDL · FOLD
1. Valuation Multiples
FOLD
Forward P/E
28.8x
17.7x
Trailing P/E
16.8x
30.5x
PEG Ratio
0.07x
N/M
EV / Revenue
8.5x
7.2x
2. Growth & Scale
AVDL
Revenue Growth (YoY)
+54.9%
+23.7%
Earnings Growth (YoY)
+0.0%
-95.5%
TTM Revenue (USD)
$249M
$634M
Market Cap
$2.1B
$4.5B
3. Profitability & Quality
AVDL
Gross Margin
94.9%
88.5%
Operating Margin
2.5%
8.6%
Net Profit Margin
-0.1%
-4.3%
Return on Equity (ROE)
-0.3%
-11.6%
4. Balance Sheet & Cash Flow
FOLD
Cash Generation (TTM)
$2.7M EBITDA
$42M EBITDA
Cash Flow Margin
1.1% EBITDA Mgn
6.6% EBITDA Mgn
Net Cash / Leverage
$1.01 Book/Sh · -0.3% ROE
$0.88 Book/Sh · -11.6% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FOLD
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
2.4% (<1st %ile)
0.2% (<1st %ile)
Put/Call OI Skew
N/A
0.03x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
FOLD
OpEx & R&D Intensity
N/A
79.9% of Rev ($507M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AVDL (5) vs FOLD (5)
Institutional Metric
AVDL
FOLD
Criterion
Row Edge
Market Capitalization
Scale
$2.1B
$4.5B
Larger Scale
FOLD
Trailing P/E Ratio
Valuation
16.8x
30.5x
Lower Multiple
AVDL
Forward P/E Ratio
Valuation
28.8x
17.7x
Lower Multiple
FOLD
Revenue Growth (YoY)
Growth
+54.9%
+23.7%
Higher Growth
AVDL
Operating Margin (TTM)
Profitability
2.5%
8.6%
Higher Margin
FOLD
Net Profit Margin
Profitability
-0.1%
-4.3%
Higher Margin
AVDL
Return on Equity (ROE)
Capital Efficiency
-0.3%
-11.6%
Higher ROE
AVDL
52-Week Range Position
Momentum
89% ($6–$24)
100% ($6–$14)
Stronger Trend
FOLD
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol
0.27β · 2% Vol
Lower Realized Risk
FOLD
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY)
59.4 / 100 (HOLD)
Higher Composite
AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M
$634M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9%
88.5%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev
N/M PEG · 7.2x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE)
$42M EBITDA ($0.88 Book/Sh · -11.6% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
AVDL +0.44 pp
AVDL:
+0.65%
·
FOLD:
+0.21%
3M Horizon
FOLD +43.28 pp
AVDL:
+15.72%
·
FOLD:
+59.0%
6M Horizon
FOLD +43.52 pp
AVDL:
+61.49%
·
FOLD:
+105.01%
1Y Horizon
AVDL +58.86 pp
AVDL:
+160.41%
·
FOLD:
+101.55%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs FOLD. Trailing 12-month operating profitability (AVDL 2.5% vs FOLD 8.6%) and valuation multiples (AVDL 28.8x vs FOLD 17.7x Forward P/E) are benchmarked directly in Pillar 4 below.
AVDL ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $249M
Gross Margin 94.9%
Op. Margin 2.5%
ROE / Fwd P/E -0.3% · 28.8x
FOLD ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $634M
Gross Margin 88.5%
Op. Margin 8.6%
ROE / Fwd P/E -11.6% · 17.7x
AVDL
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
2.4%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
FOLD
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
0.2%
IV Percentile
<1st %ile
Put/Call OI Skew
0.03x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
AVDL Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
FOLD Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.5B market capitalization and 8.6% operating margin.
OpEx & R&D Reinvestment
79.9% of Rev ($507M)
90D Engineering Disclosures
0 Published
Investor FAQ AVDL vs FOLD Key Questions & Quantitative Answers
Is AVDL or FOLD a better stock to buy right now?
As of Apr 24, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Amicus Therapeutics, Inc (FOLD) on higher Unified Composite conviction (62.9/100 BUY vs. 59.4/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Profitability & Quality), while FOLD wins 4–2 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus FOLD at $14.49 (17.7x Forward P/E, 8.6% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. FOLD 59.4/100 HOLD) and 0.14β · 2% Vol risk profile, whereas FOLD leads top-line expansion (+23.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Does AVDL or FOLD have stronger revenue and earnings growth?
AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with FOLD at +23.7% YoY revenue growth and -95.5% YoY earnings growth on $634M TTM revenue (88.5% gross margin, 8.6% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $634M for FOLD. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 79.9% of Rev ($507M) (0 disclosures) for FOLD.
Is AVDL or FOLD cheaper on valuation?
FOLD screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas FOLD trades at 17.7x Forward P/E, 30.5x Trailing P/E, N/M PEG, and 7.2x EV/Revenue (6.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus FOLD (-11.6% ROE) capital efficiency.
How is options market volatility positioned on AVDL vs FOLD?
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, FOLD carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 2% Vol realized risk).
Avadel Pharmaceuticals plc Ordinary Share (AVDL) Research Suite
Amicus Therapeutics, Inc (FOLD) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Apr 24, 2026. For educational research only; not investment advice.